AstraZeneca Completes Divestment of non-US Rights to GI Drug
By

AstraZeneca has completed its agreement with Tillotts Pharma AG, part of the Zeria Group, for the divestment of global rights, outside the US, to Entocort (budesonide), a gastroenterology medicine for patients with mild to moderate Crohn's disease and ulcerative colitis.

Upon completion of the transaction, Tillotts paid AstraZeneca $215 million for the rights to sell and develop Entocort capsules and enema formulations outside the US. The transaction does not include the transfer of any AstraZeneca employees or facilities.

Source: AstraZeneca

Leave a Reply

Your email address will not be published. Required fields are marked *